Clinical trial
Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas
NCT00038441 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038441 |
|---|---|
| Title | Phase I Trial of Intramural Injection of DTI-015 for Recurrent Malignant Gliomas |
| Official title | Phase I Trial of Intratumoral Injection of DTI-015 for Recurrent Malignant Gliomas |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Direct Therapeutics Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Glioma, Brain Neoplasms |
| Intervention type | Drug |
| Interventions | DTI-015 |
| Enrollment | 39 |
| Start date | Sep 1, 1995 |
| Primary completion | Feb 1, 2003 |
| Completion | Aug 1, 2005 |
| First posted | May 31, 2002 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: